Preparation of asymmetric urea derivatives that target prostate-specific membrane antigen for SPECT imaging

Journal of Medicinal Chemistry

Volumn 56, Issue 20, 2013, Pages 7890-7901

  Harada, Naoya ^a   Kimura, Hiroyuki ^a   Ono, Masahiro ^a   Saji, Hideo ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 (PHOSPHONOMETHYL)PENTANEDIOIC ACID; 2 [3 (1 CARBOXY 2 MERCAPTOETHYL)]UREIDO PENTANE DIOIC ACID; 2 [3 1 CARBOXY 2 [[1 [5 CARBOXY 5 [3 (3 IODOBENZAMIDO)PROPANAMIDO]PENTYL 2,5 DIOXOPYRROLIDIN 3 YL]THIO]ETHYL]UREIDO]PENTANEDIOIC ACID; 2 [3 1 CARBOXY 2 [[1 [5 CARBOXY 5 [4 (3 IODOBENZAMIDO)BUTANAMIDO]PENTYL 2,5 DIOXOPYRROLIDIN 3 YL]THIO]ETHYL]UREIDO]PENTANEDIOIC ACID; 2 [3 1 CARBOXY 2 [[1 [5 CARBOXY 5 [5 (3 IODOBENZAMIDO)PENTANAMIDO]PENTYL 2,5 DIOXOPYRROLIDIN 3 YL]THIO]ETHYL]UREIDO]PENTANEDIOIC ACID; 2 [3 [1 CARBOXY 2 [(1 METHYL 2,5 DIOXOPYRROLIDINE 3 YL)THIO]ETHYL]UREIDO]PENTANEDIOIC ACID; 2 [3 [1 CARBOXY 2 [[1 [5 CARBOXY 5 (3 IODOBENZAMIDO)PENTYL 2,5 DIOXOPYRROLIDIN 3 YL]THIO]ETHYL]UREIDO]]PENTANEDIOIC ACID; 2 [3 [1 CARBOXY 2 [[1 [5 CARBOXY 5 [2 (3 IODOBENZAMIDO)ACETAMIDO]PENTYL] 2,5 DIOXOPYRROLIDIN 3 YL]THIO]ETHYL]UREIDO]PENTANEDIOIC ACID I 123; 2 [3 [1 CARBOXY 2 [[1 [5 CARBOXY 5 [2 (METHYAMINO)ACETAMIDO]PENTYL 2,5 DIOXOPYRROLIDIN 3 YL]THIO]ETHYL]UREIDO]]PENTANEDIOIC ACID; 2 [3 [1 CARBOXY 2 [[1 [5 [2 (3 IODOBENZAMIDO)ACETAMIDO]PENTYL] 2,5 DIOXOPYRROLIDIN 3 YL]THIO]ETHYL]UREIDO]PENTANEDIOIC ACID; 2 [3 [2 [[1 [5 (2 BENZAMIDOACETAMIDO) 5 CARBOXYPENTYL] 2,5 DIOXOPYRROLIDIN 3 YL]THIO]1 CARBOXYETHYL]UREIDO]PENTANEDIOIC ACID; CARBOXYLIC ACID DERIVATIVE; CYSTEINE; IODINE 123; MALEIMIDE; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RADIOPHARMACEUTICAL AGENT; SUCCINIMIDE; UNCLASSIFIED DRUG; UREA DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PROSTATE CANCER; RADIOCHEMISTRY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR XENOGRAFT;

ANIMALS; ANTIGENS, SURFACE; BINDING, COMPETITIVE; CELL LINE, TUMOR; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; IODINE RADIOISOTOPES; MALE; MICE; MODELS, CHEMICAL; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROSTATIC NEOPLASMS; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TRANSPLANTATION, HETEROLOGOUS; UREA;

EID: 84886523569     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm400895s     Document Type: Article

References (39)

1. Siegel, R.; Naishadham, D.; Jemal, A. Cancer Statistics, 2012 CA: Cancer J. Clin. 2012, 62, 10-29
2. Cook, E.; Nelson, A. Prostate Cancer Screening Curr. Oncol. Rep. 2011, 13, 57-62
3. Hugosson, J.; Carlsson, S.; Aus, G.; Bergdahl, S.; Khatami, A.; Lodding, P.; Pihl, C.; Stranne, J.; Holmberg, E.; Lilja, H. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial Lancet Oncol. 2010, 11, 725-732
4. Stamey, T.; Yang, N.; Hay, A.; Mcneal, J.; Freiha, F.; Redwine, E. Prostate-Specific Antigen as a Serum Marker For Adenocarcinoma Of The Prostate New Engl. J. Med. 1987, 317, 909-916
5. Effert, P.; Bares, R.; Handt, S.; Wolff, J.; Bull, U.; Jakse, G. Metabolic imaging of untreated prostate cancer by positron emission tomography with (18)fluorine-labeled deoxyglucose J. Urol. 1996, 155, 994-998
6. Hain, S.; Maisey, M. Positron emission tomography for urological tumours BJU Int. 2003, 92, 159-164
7. Bouchelouche, K.; Tagawa, S.; Goldsmith, S.; Turkbey, B.; Capala, J.; Choyke, P. PET/CT Imaging and Radioimmunotherapy of Prostate Cancer Semin. Nucl. Med. 2011, 41, 29-44
8. Liu, I.; Zafar, M.; Lai, Y.; Segall, G.; Terris, M. Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer Urology 2001, 57, 108-111
9. Barinka, C.; Rojas, C.; Slusher, B.; Pomper, M. Glutamate Carboxypeptidase II in Diagnosis and Treatment of Neurologic Disorders and Prostate Cancer Curr. Med. Chem. 2012, 19, 856-870
10. Silver, D.; Pellicer, I.; Fair, W.; Heston, W.; CordonCardo, C. Prostate-specific membrane antigen expression in normal and malignant human tissues Clin. Cancer Res. 1997, 3, 81-85
11. Su, S.; Huang, I.; Fair, W.; Powell, C.; Heston, W. Alternatively Spliced Variants of Prostate-Specific Membrane Antigen RNA-Ratio of Expression As a Potential Measurement of Progression Cancer Res. 1995, 55, 1441-1443
12. Israeli, R.; Powell, C.; Fair, W.; Heston, W. Molecular-Cloning of a Complementary-DNA Encoding a Prostate-Specific Membrane Antigen Cancer Res. 1993, 53, 227-230
13. Ponsky, L.; Cherullo, E.; Starkey, R.; Nelson, D.; Neumann, D.; Zippe, C. Evaluation of preoperative ProstaScint (TM) scans in the prediction of nodal disease Prostate Cancer Prostatic Dis. 2002, 5, 132-135
14. Liu, H.; Moy, P.; Kim, S.; Xia, Y.; Rajasekaran, A.; Navarro, V.; Knudsen, B.; Bander, N. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium Cancer Res. 1997, 57, 3629-3634
15. Carter, R.; Feldman, A.; Coyle, J. Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase Proc. Natl. Acad. Sci. U. S. A. 1996, 93, 749-753
16. Tiffany, C.; Lapidus, R.; Merion, A.; Calvin, D.; Slusher, B. Characterization of the enzymatic activity of PSM: comparison with brain NAALADase Prostate 1999, 39, 28-35
17. Banerjee, S.; Foss, C.; Castanares, M.; Mease, R.; Byun, Y.; Fox, J.; Hilton, J.; Lupold, S.; Kozikowski, A.; Pomper, M. Synthesis and evaluation of technetium-99m-and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA) J. Med. Chem. 2008, 51, 4504-4517
18. Barinka, C.; Rovenska, M.; Mlcochova, P.; Hlouchova, K.; Plechanovova, A.; Majer, P.; Tsukamoto, T.; Slusher, B.; Konvalinka, J.; Lubkowski, J. Structural insight into the pharmacophore pocket of human glutamate carboxypeptidase II J. Med. Chem. 2007, 50, 3267-3273
19. Barinka, C.; Byun, Y.; Dusich, C.; Banerjee, S.; Chen, Y.; Castanares, M.; Kozikowski, A.; Mease, R.; Pomper, M.; Lubkowski, J. Interactions between Human Glutamate Carboxypeptidase II and Urea-Based Inhibitors: Structural Characterization J. Med. Chem. 2008, 51, 7737-7743
20. Kozikowski, A.; Zhang, J.; Nan, F.; Petukhov, P.; Grajkowska, E.; Wroblewski, J.; Yamamoto, T.; Bzdega, T.; Wroblewska, B.; Neale, J. Synthesis of urea-based inhibitors as active site probes of glutamate carboxypeptidase II: efficacy as analgesic agents J. Med. Chem. 2004, 47, 1729-1738
21. Banerjee, S.; Pullambhatla, M.; Byun, Y.; Green, G.; Fox, J.; Horti, A.; Mease, R.; Pomper, M. Ga-68-and In-111-Labelled Small Molecule Inhibitors of PSMA for Prostate Cancer Imaging J. Labelled Compd. Radiopharm. 2009, 52, S19
22. Banerjee, S.; Pullambhatla, M.; Byun, Y.; Nimmagadda, S.; Green, G.; Fox, J.; Horti, A.; Mease, R.; Pomper, M. Ga-68-Labeled Inhibitors of Prostate-Specific Membrane Antigen (PSMA) for Imaging Prostate Cancer J. Med. Chem. 2010, 53, 5333-5341
23. Eder, M.; Schafer, M.; Bauder-Wust, U.; Hull, W.; Wangler, C.; Mier, W.; Haberkorn, U.; Eisenhut, M. Ga-68-Complex Lipophilicity and the Targeting Property of a Urea-Based PSMA Inhibitor for PET Imaging Bioconjugate Chem. 2012, 23, 688-697
24. Lu, G.; Maresca, K.; Hillier, S.; Zimmerman, C.; Eckelman, W.; Joyal, J.; Babich, J. Synthesis and SAR of Tc-99m/Re-labeled small molecule prostate specific membrane antigen inhibitors with novel polar chelates Bioorg. Med. Chem. Lett. 2013, 23, 1557-1563
25. Nedrow-Byers, J.; Moore, A.; Ganguly, T.; Hopkins, M.; Fulton, M.; Benny, P.; Berkman, C. PSMA-targeted SPECT agents: mode of binding effect on in vitro performance Prostate 2013, 73, 355-362
26. Kularatne, S.; Zhou, Z.; Yang, J.; Post, C.; Low, P. Design, Synthesis, and Preclinical Evaluation of Prostate-Specific Membrane Antigen Targeted Tc-99m-Radioimaging Agents Mol. Pharmaceutics 2009, 6, 790-800
27. Foss, C.; Mease, R.; Fan, H.; Wang, Y.; Ravert, H.; Dannals, R.; Olszewski, R.; Heston, W.; Kozikowski, A.; Pomper, M. Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer Clin. Cancer Res. 2005, 11, 4022-4028
28. Hillier, S.; Maresca, K.; Femia, F.; Marquis, J.; Foss, C.; Nguyen, N.; Zimmerman, C.; Barrett, J.; Eckelman, W.; Pomper, M.; Joyal, J.; Babich, J. Preclinical Evaluation of Novel Glutamate-Urea-Lysine Analogues That Target Prostate-Specific Membrane Antigen as Molecular Imaging Pharmaceuticals for Prostate Cancer Cancer Res. 2009, 69, 6932-6940
29. Barrett, J.; Coleman, R.; Goldsmith, S.; Vallabhajosula, S.; Petry, N.; Cho, S.; Armor, T.; Stubbs, J.; Maresca, K.; Stabin, M.; Joyal, J.; Eckelman, W.; Babich, J. First-in-Man Evaluation of 2 High-Affinity PSMA-Avid Small Molecules for Imaging Prostate Cancer J. Nucl. Med. 2013, 54, 380-387
30. Wakisaka, K.; Arano, Y.; Uezono, T.; Akizawa, H.; Ono, M.; Kawai, K.; Ohomomo, Y.; Nakayama, M.; Saji, H. A novel radioiodination reagent for protein radiopharmaceuticals with l -lysine as a plasma-stable metabolizable linkage to liberate m -iodohippuric acid after lysosomal proteolysis J. Med. Chem. 1997, 40, 2643-2652
31. Mease, R.; Dusich, C.; Foss, C.; Ravert, H.; Dannals, R.; Seidel, J.; Prideaux, A.; Fox, J.; Sgouros, G.; Kozikowski, A.; Pomper, M. N -[ N -[(S)-1,3-Dicarboxypropyl]carbamoyl]-4-[F-18]fluorobenzyl- l -cysteine, [F-18]DCFBC: a new imaging probe for prostate cancer Clin. Cancer Res. 2008, 14, 3036-3043
32. Maresca, K.; Hillier, S.; Femia, F.; Keith, D.; Barone, C.; Joyal, J.; Zimmerman, C.; Kozikowski, A.; Barrett, J.; Eckelman, W.; Babich, J. A Series of Halogenated Heterodimeric Inhibitors of Prostate Specific Membrane Antigen (PSMA) as Radiolabeled Probes for Targeting Prostate Cancer J. Med. Chem. 2009, 52, 347-357
33. Majumdar, S.; Burgman, M.; Haselton, N.; Grinnell, S.; Ocampo, J.; Pasternak, A.; Pasternak, G. Generation of novel radiolabeled opiates through site-selective iodination Bioorg. Med. Chem. Lett. 2011, 21, 4001-4004
34. Camphausen, K.; Sproull, M.; Tantama, S.; Venditto, V.; Sankineni, S.; Scott, T.; Brechbiel, M. Evaluation of chelating agents as anti-angiogenic therapy through copper chelation Bioorg. Med. Chem. 2004, 12, 5133-5140
35. Cheng, Y.; Prusoff, W. Relationship Between Inhibition Constant (K1) and Concentration of Inhibitor Which Causes 50 Per Cent Inhibition (I50) of an Enzymatic-Reaction Biochem. Pharmacol. 1973, 22, 3099-3108
36. Mesters, J.; Barinka, C.; Li, W.; Tsukamoto, T.; Majer, P.; Slusher, B.; Konvalinka, J.; Hilgenfeld, R. Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer EMBO J. 2006, 25, 1375-1384
37. Barinka, C.; Starkova, J.; Konvalinka, J.; Lubkowski, J. A high-resolution structure of ligand-free human glutamate carboxypeptidase II Acta Crystallogr., Sect. F: Struct. Biol. Cryst. Commun. 2007, 63, 150-153
38. Afshar-Oromieh, A.; Haberkorn, U.; Eder, M.; Eisenhut, M.; Zechmann, C. [Ga-68]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with F-18-FECH Eur. J. Nucl. Med. Mol. Imaging 2012, 39, 1085-1086
39. Afshar-Oromieh, A.; Malcher, A.; Eder, M.; Eisenhut, M.; Linhart, H.; Hadaschik, B.; Holland-Letz, T.; Giesel, F.; Kratochwil, C.; Haufe, S.; Haberkorn, U.; Zechmann, C. PET imaging with a [Ga-68]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions Eur. J. Nucl. Med. Mol. Imaging 2013, 40, 486-495